DK1126828T3 - Oral indgivelse af adenosin-analoger - Google Patents

Oral indgivelse af adenosin-analoger

Info

Publication number
DK1126828T3
DK1126828T3 DK99960184T DK99960184T DK1126828T3 DK 1126828 T3 DK1126828 T3 DK 1126828T3 DK 99960184 T DK99960184 T DK 99960184T DK 99960184 T DK99960184 T DK 99960184T DK 1126828 T3 DK1126828 T3 DK 1126828T3
Authority
DK
Denmark
Prior art keywords
composition
oral administration
dosage form
disclosed
adenosine analogues
Prior art date
Application number
DK99960184T
Other languages
English (en)
Inventor
Simeon M Wrenn Jr
Original Assignee
Mayne Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayne Pharma Plc filed Critical Mayne Pharma Plc
Application granted granted Critical
Publication of DK1126828T3 publication Critical patent/DK1126828T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK99960184T 1998-11-04 1999-11-01 Oral indgivelse af adenosin-analoger DK1126828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/185,909 US6174873B1 (en) 1998-11-04 1998-11-04 Oral administration of adenosine analogs
PCT/US1999/025676 WO2000025758A1 (en) 1998-11-04 1999-11-01 Oral administration of adenosine analogs

Publications (1)

Publication Number Publication Date
DK1126828T3 true DK1126828T3 (da) 2009-06-15

Family

ID=22682923

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960184T DK1126828T3 (da) 1998-11-04 1999-11-01 Oral indgivelse af adenosin-analoger

Country Status (13)

Country Link
US (1) US6174873B1 (da)
EP (1) EP1126828B1 (da)
JP (2) JP5523647B2 (da)
AT (1) ATE427103T1 (da)
AU (1) AU774055B2 (da)
CA (1) CA2347913C (da)
DE (1) DE69940674D1 (da)
DK (1) DK1126828T3 (da)
ES (1) ES2322724T3 (da)
IL (2) IL142801A0 (da)
MX (1) MXPA01004547A (da)
PT (1) PT1126828E (da)
WO (1) WO2000025758A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226997B1 (en) 1997-12-11 2010-04-28 Alcafleu Man Gmbh & Co Kg Method for producing lithium, sodium, potassium, calcium and magnesium salts of fludarabin phosphate purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99,5% pure
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
AU2001282717A1 (en) * 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
ES2350307T3 (es) * 2000-09-06 2011-01-20 Mitsubishi Tanabe Pharma Corporation Preparaciones granulares para administración oral.
CA2406446A1 (en) * 2000-09-18 2002-03-21 Gregory Paul Handreck Diphosphonate solutions
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
US20030124178A1 (en) * 2001-12-28 2003-07-03 Haley Jeffrey T. Soft, adherent, soluble oral patch
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
RU2004123637A (ru) * 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
US7153840B2 (en) * 2002-05-24 2006-12-26 Sicor, Inc. Aqueous fludarabine phosphate composition
US20080220107A1 (en) * 2002-09-03 2008-09-11 Pharmacure Health Care Ab Nasal spray apparatus
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
PL1608344T3 (pl) * 2003-03-28 2011-01-31 Ares Trading Sa Doustne formulacje kladrybiny
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
JP2007526291A (ja) * 2004-03-05 2007-09-13 ケンブリッジ・バイオテクノロジー・リミテッド アデノシン受容体アゴニスト
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
KR20080047402A (ko) * 2005-08-26 2008-05-28 안티소마 피엘씨 Ｄｍｘａａ를 포함하는 암 치료용 조합물
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US8282956B2 (en) 2006-06-13 2012-10-09 Nippon Shinyaku Co. Ltd. Coated tablet
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010133629A1 (en) * 2009-05-19 2010-11-25 Grindeks, A Joint Stock Company Stable pharmaceutical composition of fludarabine phosphate
EP2428201A1 (en) * 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7464B (en) * 1973-01-16 1974-11-27 J Voorhees Treatment of proliferating skin diseases with papavine alkaloids
US3923785A (en) 1974-04-22 1975-12-02 Parke Davis & Co (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4163839A (en) 1977-12-09 1979-08-07 Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai Isocoformycin and a process for the production thereof
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
JPS5951223A (ja) * 1982-09-17 1984-03-24 Sumitomo Chem Co Ltd 製剤組成物
US4713372A (en) 1984-03-16 1987-12-15 Warner-Lambert Company 2-chloropentostatin compound having adenosine diaminase inhibitory activity
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
JPS649932A (en) * 1987-07-01 1989-01-13 Toyo Capsel Kk Soft capsule preparation using newly combined component as the base
US5521162A (en) 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US5132291A (en) 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
CA2054771A1 (en) * 1989-05-15 1990-11-16 Hiroaki Mitsuya Method of treatment of hepatitis
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06316524A (ja) * 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5366960A (en) 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5663155A (en) 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
JPH09100226A (ja) * 1995-10-03 1997-04-15 Sumitomo Pharmaceut Co Ltd 腸溶・徐放性コーティング製剤の製法
AU6771198A (en) * 1997-03-24 1998-10-20 Glaxo Group Limited Method for treating b-cell tumors with ara-g nucleoside derivatives
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
MX336654B (es) * 2010-12-14 2016-01-27 Hendrickson Usa Llc Placa superior para eje de vehiculo.

Also Published As

Publication number Publication date
MXPA01004547A (es) 2003-07-21
ATE427103T1 (de) 2009-04-15
ES2322724T3 (es) 2009-06-25
JP5523647B2 (ja) 2014-06-18
IL142801A0 (en) 2002-03-10
EP1126828B1 (en) 2009-04-01
JP2011057712A (ja) 2011-03-24
JP2002528487A (ja) 2002-09-03
EP1126828A1 (en) 2001-08-29
JP5580726B2 (ja) 2014-08-27
WO2000025758A1 (en) 2000-05-11
PT1126828E (pt) 2009-05-25
IL142801A (en) 2006-04-10
US6174873B1 (en) 2001-01-16
AU774055B2 (en) 2004-06-17
CA2347913A1 (en) 2000-05-11
AU1711000A (en) 2000-05-22
DE69940674D1 (de) 2009-05-14
CA2347913C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
DK1126828T3 (da) Oral indgivelse af adenosin-analoger
DE69940769D1 (de) Orale flüssige zusammensetzungen
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
ES2090368T3 (es) Composiciones farmaceuticas que contienen glucosaminoglicanos absorbibles por via oral.
IL141762A0 (en) New oral formulations
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
DE60019334D1 (de) Antivirale arznei
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE281171T1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
NO955084D0 (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
GEP20043377B (en) Pharmaceutical Complex
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
DK1144420T3 (da) Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf
HRP20000704B1 (en) Controlled release peroral compositions of levosimendan
ATE194498T1 (de) Wasserfreies mittel auf lactulosebasis
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.